Xenon Pharmaceuticals Inc
XENE
Company Profile
Business description
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Contact
200-3650 Gilmore Way
BurnabyBCV5G 4W8
CANT: +1 604 484-3300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
327
Stocks News & Analysis
stocks
How I lost all my savings through a poor investment decision
With first timers at risk of poor investment decisions and an interest in speculative stocks, I explore my biggest investing mistake.
stocks
Chart of the Week: Morningstar’s forecast for CSL’s future
We see gross margin expansion on efficiencies and limited tariff impact
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,070.50 | 41.00 | 0.45% |
| CAC 40 | 7,827.45 | 44.57 | -0.57% |
| DAX 40 | 23,666.81 | 55.48 | 0.23% |
| Dow JONES (US) | 46,121.28 | 171.50 | -0.37% |
| FTSE 100 | 9,250.43 | 27.11 | 0.29% |
| HKSE | 26,605.33 | 86.68 | 0.33% |
| NASDAQ | 22,497.86 | 75.62 | -0.33% |
| Nikkei 225 | 45,698.48 | 68.17 | 0.15% |
| NZX 50 Index | 13,123.67 | 57.64 | -0.44% |
| S&P 500 | 6,637.97 | 18.95 | -0.28% |
| S&P/ASX 200 | 8,778.70 | 40.80 | 0.47% |
| SSE Composite Index | 3,859.62 | 5.98 | 0.16% |